Jasper Therapeutics Inc. Insider Trading
JSPR
No open-market buying or selling by insiders.
The last open-market buy by an executive or director was in Sep 2025.
Get an email when JSPR's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Sep 22, 2025 | Thomas G Wiggans Director | Bought | 41,000 | $2.43 | 100K | 820% | Form 4 |
| Sep 22, 2025 | Svetlana Lucas Director | Bought | 20,000 | $2.43 | 49K | New | Form 4 |
| Sep 22, 2025 | Ron Martell President and CEO | Bought | 41,000 | $2.43 | 100K | 124% | Form 4 |
| Sep 22, 2025 | Judith Anne Shizuru Director | Bought | 41,000 | $2.43 | 100K | 35% | Form 4 |
| Dec 12, 2024 | Jeetinder Singh Mahal Chief Operating Officer | Sold10b5-1 plan | 900 | $22.11 | 20K | 3.5% | Form 4 |
- Sep 22, 2025Thomas G WiggansDirector · bought 41,000 at $2.43100K820% of stake
- Sep 22, 2025Svetlana LucasDirector · bought 20,000 at $2.4349KNew position
- Sep 22, 2025Ron MartellPresident and CEO · bought 41,000 at $2.43100K124% of stake
- Sep 22, 2025Judith Anne ShizuruDirector · bought 41,000 at $2.43100K35% of stake
- Dec 12, 202410b5-1 planJeetinder Singh MahalChief Operating Officer · sold 900 at $22.1120K3.5% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with JSPR
Spot a number that looks wrong? Check it in JSPR's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing JSPR
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.